Abstract
(5Z,9Z)-11-Phenylundeca-5,9-dienoic acid was stereoselectively synthesized, based on original cross-cyclomagnesiation of 2-(hepta-5,6-dien-1-yloxy)tetrahydro-2H-pyran and buta-2,3-dien-1-ylbenzene with EtMgBr in the presence of the Cp2TiCl2 catalyst giving 2,5-dialkylydenemagnesacyclopentane in 86% yield. The acid hydrolysis of the product and Jones oxidation of the resulting 2-{[(5Z,9Z)-11-phenylundeca-5,9-dien-1-yl]oxy}tetrahydro-2Н-pyran afforded (5Z,9Z)-11-phenylundeca-5,9-dienoic acid in an overall yield of 75%. A high inhibitory activity of the synthesized acid with respect to human topoisomerase I (hTop1) and II (hTop2α) was detected. Resorting to the data of molecular docking, a mechanism of inhibition was proposed.
Keywords: Cyclomagnesiation, docking, fatty acids, homogeneous catalysis, novel topoisomerase I and IIα inhibitors, stereoselective synthesis of 5Z, 9Z-dienoic acid.
Graphical Abstract
Current Cancer Drug Targets
Title:11-Phenylundeca-5Z,9Z-dienoic Acid: Stereoselective Synthesis and Dual Topoisomerase I/IIα Inhibition
Volume: 15 Issue: 6
Author(s): Vladimir A. D’yakonov, Lilya U. Dzhemileva, Aleksey A. Makarov, Alfiya R. Mulyukova, Dmitry S. Baevd, Elza K. Khusnutdinova, Tatiana G. Tolstikova and Usein M. Dzhemilev
Affiliation:
Keywords: Cyclomagnesiation, docking, fatty acids, homogeneous catalysis, novel topoisomerase I and IIα inhibitors, stereoselective synthesis of 5Z, 9Z-dienoic acid.
Abstract: (5Z,9Z)-11-Phenylundeca-5,9-dienoic acid was stereoselectively synthesized, based on original cross-cyclomagnesiation of 2-(hepta-5,6-dien-1-yloxy)tetrahydro-2H-pyran and buta-2,3-dien-1-ylbenzene with EtMgBr in the presence of the Cp2TiCl2 catalyst giving 2,5-dialkylydenemagnesacyclopentane in 86% yield. The acid hydrolysis of the product and Jones oxidation of the resulting 2-{[(5Z,9Z)-11-phenylundeca-5,9-dien-1-yl]oxy}tetrahydro-2Н-pyran afforded (5Z,9Z)-11-phenylundeca-5,9-dienoic acid in an overall yield of 75%. A high inhibitory activity of the synthesized acid with respect to human topoisomerase I (hTop1) and II (hTop2α) was detected. Resorting to the data of molecular docking, a mechanism of inhibition was proposed.
Export Options
About this article
Cite this article as:
D’yakonov Vladimir A., Dzhemileva Lilya U., Makarov Aleksey A., Mulyukova Alfiya R., S. Baevd Dmitry, Khusnutdinova Elza K., Tolstikova Tatiana G. and Dzhemilev Usein M., 11-Phenylundeca-5Z,9Z-dienoic Acid: Stereoselective Synthesis and Dual Topoisomerase I/IIα Inhibition , Current Cancer Drug Targets 2015; 15 (6) . https://dx.doi.org/10.2174/1568009615666150506093155
DOI https://dx.doi.org/10.2174/1568009615666150506093155 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contribution of Electrochemistry to the Biomedical and Pharmaceutical Analytical Sciences
Current Drug Delivery An Efficient Cancer Classification Model for CT/MRI/PET Fused Images
Current Medical Imaging Proteomic Strategies for the Analysis of Carbonyl Groups on Proteins
Current Protein & Peptide Science 13C Metabolic Flux Analysis: From the Principle to Recent Applications
Current Bioinformatics The Two Faces of Iminoalditols: Powerful Inhibitors Trigger Glycosidase Activation
Current Enzyme Inhibition Analytical Methods for the Quantification of Selenium Species in Biological Matrix: Where are We?
Current Nutraceuticals Fecal DNA Genotyping: A Non-invasive Approach to Characterize Mouse Models for Nutrigenomics Cancer Chemoprevention Studies
Current Pharmacogenomics and Personalized Medicine Identification and Determination of Potential Impurities Present in the Acyclovir Drug Substance by GC-MS
Current Pharmaceutical Analysis Enkephalin-Fentanyl Multifunctional Opioids as Potential Neuroprotectants for Ischemic Stroke Treatment
Current Pharmaceutical Design The Emerging Potential of By-Products as Platforms for Drug Delivery Systems
Current Drug Targets Contribution of Resveratrol in the Development of Novel Urease Inhibitors: Synthesis, Biological Evaluation and Molecular Docking Studies
Combinatorial Chemistry & High Throughput Screening The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism The Potential Role of Claudins in Regulation of Metastasis and Development of Drug Resistance in Breast Cancer
Clinical Cancer Drugs Interaction Between DNA/histone Methyltransferases and their Inhibitors
Current Medicinal Chemistry Brain Tumor Segmentation Using Deep Belief Networks and Pathological Knowledge
CNS & Neurological Disorders - Drug Targets The Therapeutical Potential of a Novel Pterocarpanquinone LQB-118 to Target Inhibitor of Apoptosis Proteins in Acute Myeloid Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Synthesis, Biological and Computational Evaluation of Novel 2,3-dihydro-2-aryl-4-(4- isobutylphenyl)-1,5-benzothiazepine Derivatives as Anticancer and Anti-EGFR Tyrosine Kinase Agents
Anti-Cancer Agents in Medicinal Chemistry Derivatization Coupled to Chemiluminescence Detection
Current Analytical Chemistry N-substituted Pyrrole-based Scaffolds as Potential Anticancer and Antiviral Lead Structures
Medicinal Chemistry Decision Support System for Lymphoma Classification
Current Medical Imaging